Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis.
Kara K LandryJessica L LyonKitty E VictoriaP Nick ChangizzadehBernard F ColeBhargavi PulluriWilliam M SikovMarie E WoodPublished in: Breast cancer (Dove Medical Press) (2022)
pCR rates were similar between patients receiving weekly or every 3-week carboplatin and were similar to those reported in prior trials with carboplatin. These data suggest that providers can choose either weekly or every 3-week carboplatin dosing without compromising the likelihood of achieving pCR.